Cover Image
市場調查報告書

中國的Telmisartan市場分析

Investigation Report on China Telmisartan Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 296863
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Telmisartan市場分析 Investigation Report on China Telmisartan Market, 2010-2019
出版日期: 2015年06月18日 內容資訊: 英文 30 Pages
簡介

Telmisartan是Boehringer Ingelheim所開發的降壓劑,1999年以「Micardis」的品牌名在美國上市。中國目前有超過3億(成人的1/3)的高血壓患者存在。但對自己症狀有適當理解的患者卻為整體40%以下,其中甚至只有1/4能實行恰當的管理。2000年末在中國上市的Telmisartan銷售額急速擴大,該市場在2005∼2014年達到年複合成長率(CAGR)35.8%的成長,此後也維持著10%左右的成長率。

本報告提供中國的Telmisartan市場相關分析,提供您中國國內的產量及醫院用銷售額·價格趨勢(過去5年份),各企業·不同投藥形態的市場佔有率,主要製造商簡介,未來性的市場趨勢預測(今後5年份)等調查資訊。

第1章 Telmisartan的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Telmisartan市場概要

  • 專利現況
  • 主要製造商
  • 市場規模

第3章 Telmisartan的銷售額分析

  • 銷售額
    • 整體
    • 各地區
  • 銷售量
    • 整體
    • 各地區

第4章 主要廠商的市場佔有率分析

  • 市場佔有率(以金額為準)
  • 市場佔有率(以數量為準)

第5章 各劑型的市場規模分析

  • 各劑型的市場佔有率(以金額為準)
  • 各劑型的市場佔有率(以數量為準)

第6章 Telmisartan的醫院用標準價格(各企業)

  • Boehringer Ingelheim
  • Beijing Wansheng Pharmaceutical Co., Ltd
  • China Resources Double Crane Pharmaceutical Co., Ltd
  • Yichang Changjiang Pharmaceutical Co., Ltd.
  • Wanbang Biopharmaceuticals (Trade Name: Bang Tan)
  • Hainan Selection Pharmaceutical Co., Ltd.
  • Dawnrays Pharmaceutical Limited

第7章 主要製造商分析

  • Boehringer Ingelheim
  • China Resources Double Crane Pharmaceutical Co., Ltd
  • Yichang Changjiang Pharmaceutical Co., Ltd.
  • Wanbang Biopharmaceutical Co., Ltd.
  • Hainan Selection Pharmaceutical Co., Ltd.

第8章 中國的Telmisartan市場未來展望

  • 市場規模的預測
  • 市場模式的預測

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1506218

The number of hypertension patients in China is estimated to surpass 300 million with one in three adults suffering from it.

Out of all the dyazides, angiotension receptor blocker (ARB) is among a new generation which grows fast. Ever since the appearance of losartan which has been first applied in the clinic, 8 kinds of similar drugs have come out for sale and there are also 5 kinds of generic drugs in China. In recent years, telmisartan could be said as the fastest-growing kind of dyazide.

First developed by Boehringer-Ingelheim (Germany) and first marketed in the US in 1999 under the trade name of Micardis, telmisartan is an oral drug for the treatment of essential hypertension which should be taken once a day. It was marketed by Boehringer-Ingelheim under the trade name of Micardis and by Glaxo Wellcome plc under the trade name of Pritor in Germany in the same year. Telmisartan entered the Philippines in Dec. 1999 and Australia, Belgium, Britain in 2000. In 2013, its sales value surpassed USD 3 billion in the world. The patent of telmisartan expired in 2014.

The active pharmaceutical ingredients (APIs) and preparations of telmisartan were introduced by Boehringer-Ingelheim into China for sales at the end of 2000. After entering China, telmisartan grows fast with annual sales value rising from less than CNY 13 million in 2005 to CNY 200 million in 2014 and CAGR during this period reaching up to 35.8% despite a slight fall in 2014. Currently, telmisartan in the Chinese market mainly come from the following companies: Boehringer-Ingelheim (Germany), China Resources Double Crane Pharmaceutical Co., Ltd, Yichang Changjiang Pharmaceutical Co., Ltd, Wanbang Biopharmaceuticals and Hainan Selection Pharmaceutical Co., Ltd, among which Boehringer-Ingelheim (Germany) has the largest market share of over 80%, sales value in 2014 reaching up to CNY 167 million.

The market size of telmisartan in China is estimated to keep growing in the next few years.

Readers can get at least the following information from this report:

  • market size of telmisartan in China
  • competitive landscape of telmisartan in Chinese market
  • price of telmisartan made by different manufactures in China
  • market outlook of telmisartan in China

The author suggests the following groups of people purchase this report:

  • manufacturers of dyazide
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Telmisartan

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Telmisartan in China

  • 2.1. Patent and Approval Status of Telmisartan in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Telmisartan in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Telmisartan in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Telmisartan in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Telmisartan in Chinese Hospitals in 2014

  • 6.1. Boehringer-Ingelheim (Germany) (Trade Name: Micardis)
  • 6.2. Beijing Wansheng Pharmaceutical Co., Ltd (Trade Name: Shu Ni Ya)
  • 6.3. China Resources Double Crane Pharmaceutical Co., Ltd (Trade Name: Su He)
  • 6.4. Yichang Changjiang Pharmaceutical Co., Ltd (Trade Name: Ou Mei Ning)
  • 6.5. Wanbang Biopharmaceuticals (Trade Name: Bang Tan)
  • 6.6. Hainan Selection Pharmaceutical Co., Ltd (Trade Name: Li Wen)
  • 6.7. Dawnrays Pharmaceutical Limited (Trade Name: An Nei Qiang)

7. Major Manufacturers of Telmisartan in Chinese Market, 2010-2014

  • 7.1. Boehringer-Ingelheim
  • 7.2. China Resources Double Crane Pharmaceutical Co., Ltd
  • 7.3. Yichang Changjiang Pharmaceutical Co., Ltd
  • 7.4. Wanbang Biopharmaceuticals
  • 7.5. Hainan Selection Pharmaceutical Co., Ltd

8. Market Outlook of Telmisartan in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Telmisartan in China
  • Chart Approval Information of Telmisartan in China
  • Chart Sales Status of Telmisartan in China
  • Chart Sales Value of Telmisartan in China, 2010-2014
  • Chart Sales Value of Telmisartan in Some Regions in China, 2010-2014
  • Chart Sales Volume of Telmisartan in China, 2010-2014
  • Chart Sales Volume of Telmisartan in Some Regions in China, 2010-2014
  • Chart Market Share of TOP4 Manufacturers of Telmisartan for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Made by Boehringer-Ingelheim (Germany) in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Made by Yichang Changjiang in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Made by China Resources Double Crane in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Made by Hainan Selection in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Telmisartan Capsules in China, 2010-2014
  • Chart Price of Telmisartan Made by Boehringer-Ingelheim (Germany) in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by Beijing Wansheng Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by China Resources Double Crane Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by Yichang Changjiang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by Wanbang Biopharmaceuticals in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by Hainan Selection Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Telmisartan Made by Dawnrays Pharmaceutical Limited in Some Chinese Cities in 2014
Back to Top